ClinicalTrials.gg
RecruitingNCT06621264EXACT-CKDPADUpdated May 31, 2025

Exercise Activity to Improve Mobility in Patients With CKD and PAD

An interventional study of EXERCISE TRAINING WITH OR WITHOUT MEDICATION and Control (Standard treatment) in Chronic Kidney Disease Stage 3 and 4 and Peripheral Artery Disease (PAD), sponsored by University Hospital of Ferrara. Recruiting at 3 sites in Italy. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-05-31.

Sponsored by University Hospital of Ferrara · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Nov 2025, 1 year ago, but the record still lists the study as recruiting.
  • Started Oct 2024; still recruiting 2 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
124
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 176 studies in Renal Insufficiency, Chronic with a site in Italy — 26 open to participants now, 40 under way, 18 of them phase 3. Renal Insufficiency, Chronic · Italy.

Planned enrollment
90th of 143
124 · median 251
Started
2024
with 14 others
No phase
24 of 176
7 open now
Primary completion
2025-11
later than 5 of 39 live
Registered
155th of 176
by date

Among the 176 studies in Renal Insufficiency, Chronic with a site in Italy, this one is the 90th largest by planned enrollment of the 143 interventional ones that give a count, is one of 15 that started in 2024, is one of 24 with no phase, reaches primary completion later than 5 of the 39 other live ones, and was the 155th registered.

Renal Insufficiency, Chronic

3,098 studies on the registry are indexed under Renal Insufficiency, Chronic; 700 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

26 of the 176 studies in Renal Insufficiency, Chronic with a site in Italy are open now. Recruiting first, the newest first:

20 more — sign in →

All 26 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 434 Renal Insufficiency, Chronic studies recruiting now, 245 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 43 take children under 18; 80 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 176 studies in Renal Insufficiency, Chronic with a site in Italy, or all of them as a file.
02

Study summary

People affected by chronic kidney disease and concomitant diagnosed peripheral artery disease at intermediate stages, without contraindications to exercise therapy will be invited to participate in the study.

Whose providing informed consent, will be randomly assigned to one of two groups:

  1. Exercise program receiving two daily 10-minute interval walking sessions at a slow increasing speed.
  2. Control group: receiving usual care including optimal medical therapy and nutritional advice.

Patients of both groups will be measured at baseline, after the end of the exercise program (6-month) and at follow up (12-month). Outcome measures will include walking ability by the 6-minute walking test (primary outcome) and lower limbs perfusion, body composition, quality of life, laboratory outcomes and long-term hospitalizations.

Read the detailed description

People with chronic kidney disease (CKD) are exposed to a high risk of developing peripheral artery disease (PAD) and its related adverse health outcomes. This dangerous combination of pathological conditions increases overall cardiovascular risk, mortality and lower limbs amputations.

The scientific literature suggests a strategic co-management of CKD-PAD patients by multidisciplinary teams including specialists of different areas and expertise. Indeed, a common issue is that both these diseases are negatively associated with a sedentary behavior. Exercise therapy may enhance the physical functioning, the risk factors management, the lower limbs vascularization and reduce the cardiovascular risk that affects this population. Since the CKD-PAD population is less likely to be provided recommended optimal care, and considering that 2 out of 3 CKD patients have a completely sedentary behavior for several barriers to training participation, proper exercise programs should be developed. This multicenter randomized-controlled trial aims to test the effectiveness of a 6-month home-based structured walking program on physical functioning and laboratory and clinical outcomes. Purposely 100 CKD patients at KDOQI stages III or IV with concomitant PAD at Rutherford's stages I to III, aged > 18 years and without absolute contraindications to exercise training will be randomized to receive an exercise intervention (Ex) or usual care (Control, Co). The 6-month training intervention, previously tested in PAD and CKD patients, consist in two 10-minute daily interval walking sessions performed inside the home.

Patients will receive a detailed exercise prescription according to their baseline walking capacity, with the walking speed maintained at home through sound pacing by a digital metronome. The prescribed speed will be weekly increased from the 60 to the 100% of their baseline walking speed with a fixed working time throughout the program. Two serial visits during the program will be scheduled to reinforce adherence to exercise, maintained and verified by a digital application, and to control the blood pressure. Patients enrolled in the Co group will receive standard CKD-PAD care, including optimal medical therapy and nutritional advices.

The primary outcome of the study will be the variations of mobility as assessed by the 6-minute walking test at the end of the program. Secondary outcomes will include lower limbs perfusion and strength, body composition and bone mineral density, quality of life, laboratory outcomes including rate of progression of CKD and the long-term hospitalizations and mortality.

Outcome measures will be assessed by blinded operators at baseline, at the end of the program for exercise group (6-month) and at 12 months follow up.

03

Conditions studied

  • Chronic Kidney Disease Stage 3 and 4
  • Peripheral Artery Disease (PAD)

Keywords

  • Exercise therapy;
  • Mobility
  • Ageing
  • Chronic Kidney Disease
  • Peripheral artery disease
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • chronic kidney disease at KDOQI stages III or IV and concomitant Peripheral artery disease at stages I, II, III;
  • ability to walk independently;
  • cognitive function to give identified by a Mini Mental Status Examination score greater or equal to 20/30
  • absence of clinical conditions contraindicating exercise therapy (e.g., unstable angina, severe heart failure at class IV, anemia with lower than 10.0 g/dl).

Exclusion criteria

Exclusion Criteria:

  • major amputations;
  • major surgery planned in the next 3 months;
  • known comorbid conditions that may limit survival to less than 2 years;
  • inability or unwillingness to comply with protocol requirements.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
124 participants (estimated)

Study arms

  • Experimental
    Exercise group

    Patients enrolled in this group will receive a detailed 6-month exercise prescription aimed at providing in-home low fatiguingwalking training (at light-moderate intensity, or 2-3 out of 10 of the CR10 Borg's scale). The program consists of a two daily 10-minute interval walking sessions (1 minute walking : 1 minute resting) at a prescribed speed controlled by a digital metronome (https://www.youtube.com/watch?v=ki8YX\_t-0jA). The training speed will be set up according to the patients baseline walking capacity (approximately 50% lower than the habitual gait speed) and will be weekly increased until reaching the habitual gait speed. The training time will be maintained constant throughout the entire program. Exercise prescription will be updated during two intermediate hospital visits at the 1st and 3rd months. Patients will be provided with a digital application properly developed to keep pacing and to record the correct training execution.

    Behavioral: EXERCISE TRAINING WITH OR WITHOUT MEDICATION

  • Placebo comparator
    Control group

    Patients enrolled in the Co group will receive standard CKD-PAD care, including optimal medical therapy and nutritional advices

    Other: Control (Standard treatment)

Interventions

  • BehavioralEXERCISE TRAINING WITH OR WITHOUT MEDICATION

    Patients enrolled in this group will receive a detailed 6-month exercise prescription aimed at providing in-home low fatiguing walking training (at light-moderate intensity, or 2-3 out of 10 of the CR10 Borg\'s scale). The program consists of a two daily 10-minute interval walking sessions (1 minute walking : 1 minute resting) at a prescribed speed controlled by a digital metronome (https://www.youtube.com/watch?v=ki8YX\_t-0jA). The training speed will be set up according to the patients baseline walking capacity (approximately 50% lower than the habitual gait speed) and will be weekly increased until reaching the habitual gait speed. The training time will be maintained constant throughout the entire program. Exercise prescription will be updated during two intermediate hospital visits at the 1st and 3rd months. Patients will be provided with a digital application properly developed to keep pacing and to record the correct training execution.

    Also known as: exercise, rehabilitation

  • OtherControl (Standard treatment)

    Patients enrolled in the Co group will receive standard CKD-PAD care, including optimal medical therapy and nutritional advices

    Also known as: Usual care

06

What researchers measure

Primary outcomes

  1. 6-minute walking test

    The patients will be instructed to walk back and forth on a 20-meter corridor aiming at covering as much distance as possible. The total distance covered (6MWD) will be measured in meters

    Time frame: Baseline; End of program (6-month); Follow up (12-month)

Secondary outcomes

  1. Lower limbs perfusion

    This measure will be performed according to the published standards with the patient laying by dividing the blood pressure at the ankle with the systolic blood pressure.

    Time frame: Baseline; end of the program (6-month); Follow up (12-month).

  2. handgrip strength will be measured by a standard dynamometer

    both hands, patients will be asked to perform three repetitions. The peak and mean values are collected

    Time frame: Baseline; end of the program (6-month); Follow up (12-month).

  3. Quality of life will be assessed by the short-form 36 (SF-36) questionnaire

    This is a generic questionnaire that contains 36 questions referring to 8 specific domains related to patient health over the previous 4 weeks

    Time frame: Baseline; end of the program (6-month); Follow up (12-month).

  4. Bone mineral density

    bone mineral density will be measured through phalangeal quantitative ultrasound with an ultrasound signal of 1.25 MHz frequency and a methodology devoid of X-rays. The results are consistent with those obtained by standard DEXA

    Time frame: Baseline; end of the program (6-month); Follow up (12-month).

  5. lower limbs strength assessed by the 5-time sit-to-stand test

    Patients will raise up from a standard height chair with their arms folded across the chest five times as quickly as possible. The total time elapsed for completing the five repetitions is recorded in seconds

    Time frame: Baseline; end of the program (6-month); Follow up (12-month).

  6. Body mass index

    Body composition will be assessed with direct measures of height and weight. Body mass index will be calculated as the ratio between weight (in kg) and the squared height (in meters)

    Time frame: Baseline, end of the program (6-month); follow up (12-month)

  7. Circulating indexes of kidney function

    Serum creatinine will be directly measured through standard laboratory methods. The estimated glomerular filtration rate will be calculated through the 2009 Chronic Kidney Disease Epidemiology Collaboration equation

    Time frame: Baseline, end of treatment (6-month); follow up (12-month)

  8. Long-term survival rate

    All-cause mortality of the enrolled patients will be checked from the regionals datasets. In case of positive findings, the days elapsed from enrollment to the event will be recorded for additional analyses, as well as the reasons and the diagnoses.

    Time frame: Baseline, end of treatment (6-month); follow up (12-month); follow up (18-month); Follow up (24-month); FOllow up (36-month)

  9. Long-term hospitalizations

    All-cause hospitalization will be checked from the regionals datasets. In case of positive findings, the days elapsed from enrollment to the event will be recorded for additional analyses, as well as the reasons and the diagnoses.

    Time frame: Baseline, end of treatment (6-month); follow up (12-month); follow up (18-month); Follow up (24-month); FOllow up (36-month)

  10. Rate of admission to dialysis

    Number of patients that will be admitted to dialysis will be recorded and the time from enrollment to the dialysis admission will calculated

    Time frame: Baseline, end of treatment (6-month); follow up (12-month); follow up (18-month); Follow up (24-month); FOllow up (36-month)

  11. Pain-free walking distance

    During the 6-minute walking test, the distance at the onset of symptoms referred by the patient will be collected and reported

    Time frame: Baseline, end of treatment (6-month), follow up (12-month)

07

Study locations

3 of 3 sites recruiting
  • University Hospital of Ferrara
    Ferrara, Italy 44124, Italy
    Recruiting
    • Fabio Manfredini Prof. Fabio Manfredini, MD PhD · Contactfabio.manfredini@unife.it · 00390532236187
    • Fabio Manfredini, MD PhD · Principal investigator
    • Alda Storari, MD · Sub investigator
    • Sofia Straudi, MD PhD · Sub investigator
    • Nicola Lamberti, MD PhD · Sub investigator
  • Ospedale Pederzoli Peschiera del Garda
    Peschiera del Garda, Italy, Italy
    Recruiting
    • Yuri Battaglia Prof. Yuri Battaglia, MD PhD · Contactyuri.battaglia@univr.it · 0039+0456449111
    • Yuri Battaglia, MD PhD · Principal investigator
  • Grande Ospedale Metropolitano Bianchi-Melacrino-Morelli
    Reggio Calabria, Italy, Italy
    Recruiting
    • Vincenzo Panuccio Dr. Vincenzo Panuccio, MD · Contactenzopanuccio@gmail.com · 0039+0965397111
    • Vincenzo Panuccio, MD · Principal investigator
08

References and documents

Publications

  • Manfredini F, Panuccio V, Battaglia Y, Storari A, Lamberti N, Piva G, Veronesi M, Tripepi R, Rinaldo N, Crepaldi A, Momente C, Piccinini A, Traina L, Fargion AT, Straudi S, Baroni A, De Giorgi A, Martinuzzi C, Monesi M, Capitanini A, Aucella F, Cupisti A, Mallamaci F, Zoccali C, Manfredini R. Exercise therapy to improve mobility, active behaviour and quality of life of chronic kidney disease patients with peripheral artery disease: study protocol for the EXACT-CKDPAD multicentre randomised controlled trial. BMJ Open Sport Exerc Med. 2025 Jul 15;11(3):e002740. doi: 10.1136/bmjsem-2025-002740. eCollection 2025. PubMed 40672525 ↗

Individual participant data

Plan to share: Yes — The database generated for the study with anonimyzed patients\' characteristics will be available on institution public repository

Supporting information: Study protocol, Statistical analysis plan

Time frame: The study protocol, along with the statistical analysis plan will be available when published on an open access journal.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2024 (actual). Primary completion is estimated for Nov 2025, 13 months after the start.

Of 580 non-industry interventional studies with no phase under Renal Insufficiency, Chronic, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 45. This study's planned 13 months is below that.

Counting every sponsor, half of 620 studies reached it within 23 months; a quarter within 10 and three quarters within 45.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 26, 2024
First posted
Oct 1, 2024
StartActual
Oct 1, 2024
Primary completionEst.
Nov 20, 2025
CompletionEst.
Dec 31, 2026
Last update
May 31, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 31, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06621264
Collaborators
Universita di Verona, Reggio Calabria
Responsible party
Fabio Manfredini (Professor, University Hospital of Ferrara) — Principal investigator
First posted
Oct 1, 2024
Start date
Oct 1, 2024
Primary completion
Nov 20, 2025 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
May 31, 2025

Study contacts

Fabio Manfredini Prof. Fabio Manfredini, MD, PhD
Contact
fabio.manfredini@unife.it
+390532236187
Roberto Manfredini Prof. Roberto Manfredini, MD, PhD
principal investigator · Università degli Studi di Ferrara

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion